We provide you with 20 years of free, institutional-grade data for EPIX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of EPIX. Explore the full financial landscape of EPIX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| BERGER FRANKLIN M | Open Market Purchase | 76,471 | $5.35 | 2023-11-16 | |
| BVF PARTNERS L P/IL | Initial | 2022-07-21 | |||
| BIOTECH GROWTH N V | Initial | 2021-08-17 | |||
| Martin John Alexander | Initial | 2020-10-02 | |||
| Parkinson David Ross | Initial | 2020-10-01 | |||
| Thorell Marella | Initial | 2020-10-01 | |||
| Virsik Peter | Initial | 2020-10-01 | |||
| Wood David S. | Initial | 2020-10-01 | |||
| BERGER FRANKLIN M | Initial | 2020-10-01 | |||
| Glickman Richard M | Initial | 2020-10-01 | |||
| Requadt Scott | Initial | 2020-10-01 |
The information provided in this report about EPIX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
ESSA Pharma Inc(NASDAQ:EPIX) 
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prosta...
Website: http://www.essapharma.com
Founded: 2009
Full Time Employees: 25
Sector: Healthcare
Industry: Biotechnology